文章：

HER2阳性乳腺癌中细胞周期蛋白依赖性激酶4/6抑制剂的疗效与可预测性研究

Efficacy and Predictability of Cyclin-Dependent Kinase 4/6 Inhibitors in HER2-Positive Breast Cancer

原文发布日期：26 August 2025

DOI: 10.3390/cancers17172788

类型: Article

开放获取: 是

英文摘要：

HER2-positive breast cancer represents a biologically aggressive subtype associate with poor prognosis, despite advances in targeted therapies. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), initially approved for hormone-receptor-positive, HER2-negative disease, are now being explored in HER2-positive settings due to their mechanistic synergy with the HER2 signaling pathway. This review synthesizes evolving clinical evidence from trials and highlights further research into biomarker discovery. CDK4/6i may redefine treatment paradigms in HER2-positive breast cancer, offering a potential, non-chemotherapy option with durable benefit in select patient populations.

摘要翻译： 

HER2阳性乳腺癌是一种具有生物学侵袭性的亚型，与不良预后相关，尽管靶向治疗已取得进展。细胞周期蛋白依赖性激酶4/6抑制剂最初获批用于激素受体阳性、HER2阴性疾病，因其与HER2信号通路存在机制协同作用，现正被探索用于HER2阳性乳腺癌治疗。本综述整合了临床试验中的最新临床证据，并强调了对生物标志物发现的进一步研究。CDK4/6抑制剂可能重新定义HER2阳性乳腺癌的治疗模式，为特定患者群体提供一种潜在的非化疗选择，带来持久获益。

原文链接：

Efficacy and Predictability of Cyclin-Dependent Kinase 4/6 Inhibitors in HER2-Positive Breast Cancer